SCHEMBL30325883

SCHEMBL30325883

C=C(C)C(=O)Nc1ccc(-c2nn3ncnc(N)c3c2-c2ccc(C(=O)NCC(C)C)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 4/20 0.37
▸ NAMPT P43490 4/20 0.37
▸ ABL1 P00519 2/20 0.36
▸ SRC P12931 2/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ HCK P08631 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ MTOR P42345 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ EPHB4 P54760 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ PI4KB Q9UBF8 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RXFP1 Q9HBX9 2/20 0.36
▸ F2 P00734 2/20 0.35
▸ F10 P00742 2/20 0.35
▸ F7 P08709 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325933 0.93 KDR (0.37) KDRNAMPTABL1SRCPIK3CD
SCHEMBL29265892 0.88 SRC (0.38) KDRNAMPTABL1SRCMEN1
SCHEMBL30325859 0.80 RIPK2 (0.36) KDRNAMPTABL1SRCPLK4
SCHEMBL29265779 0.78 BTK (0.39) KDRNAMPTSRCEGFRF2
SCHEMBL31213973 0.78 RPS6KB1 (0.31) KDRNAMPTABL1SRCPLK4
SCHEMBL29265834 0.78 SRC (0.36) KDRSRCEGFRFGFR1FGFR3
SCHEMBL29265855 0.77 AAK1 (0.39) SRCEGFRKDM4EALDH1A1
SCHEMBL29265807 0.77 ABL1 (0.39) KDRABL1SRCPIK3CDEGFR
SCHEMBL30325952 0.77 TNK2 (0.38) KDRABL1SRCPIK3CDPLK4
SCHEMBL22676357 0.77 FGFR1 (0.54) KDRNAMPTABL1SRCPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP claimed
CN-118043327-A FGFR inhibitors and methods of use thereof 思康睿奇(上海)药业有限公司 2024-05-14 — — CN claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP disclosed
CN-118043327-A FGFR inhibitors and methods of use thereof 思康睿奇(上海)药业有限公司 2024-05-14 — — CN disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 KDR 141/4885NAMPT 814/4885ABL1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback